APOBEC3 proteins and reverse transcription

Virus Research

Volumn 134, Issue 1-2, 2008, Pages 74-85

  Aguiar, Renato S ^a   Peterlin, B Matija ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

APOBEC3; Cytidine deaminase; HIV; Restriction factors; Retroelements; Reverse transcription; Vif

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT DNA; RNA DIRECTED DNA POLYMERASE; TOLL LIKE RECEPTOR; VIF PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; DEAMINATION; ENZYME ACTIVE SITE; GENE AMPLIFICATION; GENE CLUSTER; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LONG INTERSPERSED REPEAT; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RETROPOSON; REVERSE TRANSCRIPTION; RNA TRANSCRIPTION; SHORT INTERSPERSED REPEAT; SOMATIC HYPERMUTATION; STOP CODON; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; CYTOSINE DEAMINASE; HIV; HIV INFECTIONS; HUMANS; MULTIGENE FAMILY; PROTEIN STRUCTURE, TERTIARY; RETROELEMENTS; REVERSE TRANSCRIPTION; VIRUS REPLICATION;

EID: 43049113468     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.12.022     Document Type: Article

References (158)

1. Abudu A., Takaori-Kondo A., Izumi T., Shirakawa K., Kobayashi M., Sasada A., Fukunaga K., and Uchiyama T. Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16 (2006) 1565-1570
2. Aires da Silva F., Santa-Marta M., Freitas-Vieira A., Mascarenhas P., Barahona I., Moniz-Pereira J., Gabuzda D., and Goncalves J. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J. Mol. Biol. 340 (2004) 525-542
3. Alce T.M., and Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279 (2004) 34083-34086
4. Ancuta P., Autissier P., Wurcel A., Zaman T., Stone D., and Gabuzda D. CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. J. Immunol. 176 (2006) 5760-5771
5. Ancuta P., Kunstman K.J., Autissier P., Zaman T., Stone D., Wolinsky S.M., and Gabuzda D. CD16+ monocytes exposed to HIV promote highly efficient viral replication upon differentiation into macrophages and interaction with T cells. Virology 344 (2006) 267-276
6. Arts E.J., and Wainberg M.A. Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv. Virus Res. 46 (1996) 97-163
7. Bennett R.P., Diner E., Sowden M.P., Lees J.A., Wedekind J.E., and Smith H.C. APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic. Biochem. Biophys. Res. Commun. 350 (2006) 214-219
8. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 (2004) 1392-1396
9. Bishop K.N., Holmes R.K., Sheehy A.M., and Malim M.H. APOBEC-mediated editing of viral RNA. Science 305 (2004) 645
10. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80 (2006) 8450-8458
11. Bogerd H.P., Doehle B.P., Wiegand H.L., and Cullen B.R. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3770-3774
12. Bogerd H.P., Wiegand H.L., Doehle B.P., Lueders K.K., and Cullen B.R. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucl. Acids Res. 34 (2006) 89-95
13. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K.S., Moran J.V., and Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 8780-8785
14. Bogerd H.P., Wiegand H.L., Doehle B.P., and Cullen B.R. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364 (2007) 486-493
15. Bourara K., Liegler T.J., and Grant R.M. Target Cell APOBEC3C Can Induce Limited G-to-A Mutation in HIV-1. PLoS Pathog. 3 (2007) e153
16. Brouha B., Schustak J., Badge R.M., Lutz-Prigge S., Farley A.H., Moran J.V., and Kazazian Jr. H.H. Hot L1s account for the bulk of retrotransposition in the human population. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5280-5285
17. Bukrinsky M.I., Stanwick T.L., Dempsey M.P., and Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254 (1991) 423-427
18. Caride E., Brindeiro R.M., Kallas E.G., de Sa C.A., Eyer-Silva W.A., Machado E., and Tanuri A. Sexual transmission of HIV-1 isolate showing G → A hypermutation. J. Clin. Virol. 23 (2002) 179-189
19. Chelico L., Pham P., Calabrese P., and Goodman M.F. APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat. Struct. Mol. Biol. 13 (2006) 392-399
20. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., and Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16 (2006) 480-485
21. Chiu Y.L., Soros V.B., Kreisberg J.F., Stopak K., Yonemoto W., and Greene W.C. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435 (2005) 108-114
22. Chiu Y.L., Witkowska H.E., Hall S.C., Santiago M., Soros V.B., Esnault C., Heidmann T., and Greene W.C. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 15588-15593
23. Conticello S.G., Thomas C.J., Petersen-Mahrt S.K., and Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22 (2005) 367-377
24. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80 (2006) 1067-1076
25. Dang Y., Wang X., Esselman W.J., and Zheng Y.H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80 (2006) 10522-10533
26. Deininger P.L., Moran J.V., Batzer M.A., and Kazazian Jr. H.H. Mobile elements and mammalian genome evolution. Curr. Opin. Genet. Dev. 13 (2003) 651-658
27. Delebecque F., Suspene R., Calattini S., Casartelli N., Saib A., Froment A., Wain-Hobson S., Gessain A., Vartanian J.P., and Schwartz O. Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 80 (2006) 605-614
28. Di Noia J.M., and Neuberger M.S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76 (2007) 1-22
29. Di Noia J.M., Williams G.T., Chan D.T., Buerstedde J.M., Baldwin G.S., and Neuberger M.S. Dependence of antibody gene diversification on uracil excision. J. Exp. Med. 204 (2007) 3209-3219
30. Doehle B.P., Schafer A., Wiegand H.L., Bogerd H.P., and Cullen B.R. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J. Virol. 79 (2005) 8201-8207
31. Dutko J.A., Schafer A., Kenny A.E., Cullen B.R., and Curcio M.J. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr. Biol. 15 (2005) 661-666
32. Eckstein D.A., Penn M.L., Korin Y.D., Scripture-Adams D.D., Zack J.A., Kreisberg J.F., Roederer M., Sherman M.P., Chin P.S., and Goldsmith M.A. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 15 (2001) 671-682
33. Ellery P.J., Tippett E., Chiu Y.L., Paukovics G., Cameron P.U., Solomon A., Lewin S.R., Gorry P.R., Jaworowski A., Greene W.C., Sonza S., and Crowe S.M. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178 (2007) 6581-6589
34. Esnault C., Millet J., Schwartz O., and Heidmann T. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucl. Acids Res. 34 (2006) 1522-1531
35. Eto T., Kinoshita K., Yoshikawa K., Muramatsu M., and Honjo T. RNA-editing cytidine deaminase Apobec-1 is unable to induce somatic hypermutation in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12895-12898
36. Franca R., Spadari S., and Maga G. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism. Med. Sci. Monit. 12 (2006) RA92-RA98
37. Gallois-Montbrun S., Kramer B., Swanson C.M., Byers H., Lynham S., Ward M., and Malim M.H. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81 (2007) 2165-2178
38. Guo F., Cen S., Niu M., Saadatmand J., and Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80 (2006) 11710-11722
39. Hache G., Liddament M.T., and Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280 (2005) 10920-10924
40. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4 (2004) 868-877
41. Harris R.S., Sale J.E., Petersen-Mahrt S.K., and Neuberger M.S. AID is essential for immunoglobulin V gene conversion in a cultured B cell line. Curr. Biol. 12 (2002) 435-438
42. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
43. Hatziioannou T., Perez-Caballero D., Yang A., Cowan S., and Bieniasz P.D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10774-10779
44. Hill M.S., Mulcahy E.R., Gomez M.L., Pacyniak E., Berman N.E., and Stephens E.B. APOBEC3G expression is restricted to neurons in the brains of pigtailed macaques. AIDS Res. Hum. Retroviruses 22 (2006) 541-550
45. Holmes R.K., Koning F.A., Bishop K.N., and Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282 (2007) 2587-2595
46. Holmes R.K., Malim M.H., and Bishop K.N. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem. Sci. 32 (2007) 118-128
47. Huthoff H., and Malim M.H. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology 334 (2005) 147-153
48. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., and Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucl. Acids Res. 35 (2007) 7096-7108
49. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., and Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 (2002) 285-296
50. Jost S., Turelli P., Mangeat B., Protzer U., and Trono D. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J. Virol. 81 (2007) 10588-10596
51. Kaiser S.M., and Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80 (2006) 875-882
52. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., and Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77 (2003) 11398-11407
53. Kazazian Jr. H.H. Genetics. L1 retrotransposons shape the mammalian genome. Science 289 (2000) 1152-1153
54. Kazazian Jr. H.H. Mobile elements: drivers of genome evolution. Science 303 (2004) 1626-1632
55. Kazazian Jr. H.H., and Goodier J.L. LINE drive. retrotransposition and genome instability. Cell 110 (2002) 277-280
56. Kazazian Jr. H.H., and Moran J.V. The impact of L1 retrotransposons on the human genome. Nat. Genet. 19 (1998) 19-24
57. Keckesova Z., Ylinen L.M., and Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10780-10785
58. Kieffer T.L., Kwon P., Nettles R.E., Han Y., Ray S.C., and Siliciano R.F. G → A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 79 (2005) 1975-1980
59. Kinomoto M., Kanno T., Shimura M., Ishizaka Y., Kojima A., Kurata T., Sata T., and Tokunaga K. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucl. Acids Res. 35 (2007) 2955-2964
60. Kobayashi M., Takaori-Kondo A., Shindo K., Abudu A., Fukunaga K., and Uchiyama T. APOBEC3G targets specific virus species. J. Virol. 78 (2004) 8238-8244
61. Kolosha V.O., and Martin S.L. In vitro properties of the first ORF protein from mouse LINE-1 support its role in ribonucleoprotein particle formation during retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10155-10160
62. Kolosha V.O., and Martin S.L. High-affinity, non-sequence-specific RNA binding by the open reading frame 1 (ORF1) protein from long interspersed nuclear element 1 (LINE-1). J. Biol. Chem. 278 (2003) 8112-8117
63. Korin Y.D., and Zack J.A. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72 (1998) 3161-3168
64. Kozak S.L., Marin M., Rose K.M., Bystrom C., and Kabat D. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281 (2006) 29105-29119
65. Kreisberg J.F., Yonemoto W., and Greene W.C. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203 (2006) 865-870
66. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., Funke R., Gage D., Harris K., Heaford A., Howland J., Kann L., Lehoczky J., LeVine R., McEwan P., McKernan K., Meldrim J., Mesirov J.P., Miranda C., Morris W., Naylor J., Raymond C., Rosetti M., Santos R., Sheridan A., Sougnez C., Stange-Thomann N., Stojanovic N., Subramanian A., Wyman D., Rogers J., Sulston J., Ainscough R., Beck S., Bentley D., Burton J., Clee C., Carter N., Coulson A., Deadman R., Deloukas P., Dunham A., Dunham I., Durbin R., French L., Grafham D., Gregory S., Hubbard T., Humphray S., Hunt A., Jones M., Lloyd C., McMurray A., Matthews L., Mercer S., Milne S., Mullikin J.C., Mungall A., Plumb R., Ross M., Shownkeen R., Sims S., Waterston R.H., Wilson R.K., Hillier L.W., McPherson J.D., Marra M.A., Mardis E.R., Fulton L.A., Chinwalla A.T., Pepin K.H., Gish W.R., Chissoe S.L., Wendl M.C., Delehaunty K.D., Miner T.L., Delehaunty A., Kramer J.B., Cook L.L., Fulton R.S., Johnson D.L., Minx P.J., Clifton S.W., Hawkins T., Branscomb E., Predki P., Richardson P., Wenning S., Slezak T., Doggett N., Cheng J.F., Olsen A., Lucas S., Elkin C., Uberbacher E., Frazier M., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
67. Lee Y.N., and Bieniasz P.D. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3 (2007) e10
68. Lee G.S., Brandt V.L., and Roth D.B. B cell development leads off with a base hit: dU:dG mismatches in class switching and hypermutation. Mol Cell 16 (2004) 505-508
69. Lehmann D.M., Galloway C.A., MacElrevey C., Sowden M.P., Wedekind J.E., and Smith H.C. Functional characterization of APOBEC-1 complementation factor phosphorylation sites. Biochim. Biophys. Acta 1773 (2007) 408-418
70. Liao W., Hong S.H., Chan B.H., Rudolph F.B., Clark S.C., and Chan L. APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem. Biophys. Res. Commun. 260 (1999) 398-404
71. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
72. Liu B., Yu X., Luo K., Yu Y., and Yu X.F. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78 (2004) 2072-2081
73. Liu B., Sarkis P.T., Luo K., Yu Y., and Yu X.F. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79 (2005) 9579-9587
74. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., and Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78 (2004) 11841-11852
75. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., and Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81 (2007) 7238-7248
76. Madani N., and Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72 (1998) 10251-10255
77. Madani N., and Kabat D. Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J. Virol. 74 (2000) 5982-5987
78. Mahieux R., Suspene R., Delebecque F., Henry M., Schwartz O., Wain-Hobson S., and Vartanian J.P. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 86 (2005) 2489-2494
79. Malim M.H. Natural resistance to HIV infection: the Vif-APOBEC interaction. C. R. Biol. 329 (2006) 871-875
80. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
81. Mangeat B., Turelli P., Liao S., and Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279 (2004) 14481-14483
82. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., and Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (2003) 21-31
83. Matsumoto T., Marusawa H., Endo Y., Ueda Y., Matsumoto Y., and Chiba T. Expression of APOBEC2 is transcriptionally regulated by NF-kappaB in human hepatocytes. FEBS Lett. 580 (2006) 731-735
84. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., and Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81 (2007) 7099-7110
85. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 (2004) 7792-7798
86. Mehle A., Thomas E.R., Rajendran K.S., and Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281 (2006) 17259-17265
87. Mehle A., Wilson H., Zhang C., Brazier A.J., McPike M., Pery E., and Gabuzda D. Identification of an APOBEC3G binding site in HIV-1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81 (2007) 13235-13241
88. Mikl M.C., Watt I.N., Lu M., Reik W., Davies S.L., Neuberger M.S., and Rada C. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell Biol. 25 (2005) 7270-7277
89. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., and Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81 (2007) 13346-13353
90. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Lower J., Cichutek K., Flory E., Schumann G.G., and Munk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281 (2006) 22161-22172
91. Muckenfuss H., Kaiser J.K., Krebil E., Battenberg M., Schwer C., Cichutek K., Munk C., and Flory E. Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucl. Acids Res. 35 (2007) 3784-3796
92. Navarro F., Bollman B., Chen H., Konig R., Yu Q., Chiles K., and Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 333 (2005) 374-386
93. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., and Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 (2005) 166-170
94. Nguyen D.H., Gummuluru S., and Hu J. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J. Virol. 81 (2007) 4465-4472
95. Niewiadomska A.M., Tian C., Tan L., Wang T., Sarkis P.T., and Yu X.F. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J. Virol. 81 (2007) 9577-9583
96. OhAinle M., Kerns J.A., Malik H.S., and Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80 (2006) 3853-3862
97. Okeoma C.M., Lovsin N., Peterlin B.M., and Ross S.R. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445 (2007) 927-930
98. Paillart J.C., Marquet R., Skripkin E., Ehresmann C., and Ehresmann B. Dimerization of retroviral genomic RNAs: structural and functional implications. Biochimie 78 (1996) 639-653
99. Peng G., Lei K.J., Jin W., Greenwell-Wild T., and Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203 (2006) 41-46
100. Peng G., Greenwell-Wild T., Nares S., Jin W., Lei K.J., Rangel Z.G., Munson P.J., and Wahl S.M. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110 (2007) 393-400
101. Pido-Lopez J., Whittall T., Wang Y., Bergmeier L.A., Babaahmady K., Singh M., and Lehner T. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J. Immunol. 178 (2007) 1671-1679
102. Pion M., Granelli-Piperno A., Mangeat B., Stalder R., Correa R., Steinman R.M., and Piguet V. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J. Exp. Med. 203 (2006) 2887-2893
103. Prak E.T., and Kazazian Jr. H.H. Mobile elements and the human genome. Nat. Rev. Genet. 1 (2000) 134-144
104. Prochnow C., Bransteitter R., Klein M.G., Goodman M.F., and Chen X.S. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445 (2007) 447-451
105. Rada C., Di Noia J.M., and Neuberger M.S. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Mol. Cell 16 (2004) 163-171
106. Randolph G.J., Sanchez-Schmitz G., Liebman R.M., and Schakel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 196 (2002) 517-527
107. Ribeiro A.C., Maia e Silva A., Santa-Marta M., Pombo A., Moniz-Pereira J., Goncalves J., and Barahona I. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J. Virol. 79 (2005) 823-833
108. Rogozin I.B., Basu M.K., Jordan I.K., Pavlov Y.I., and Koonin E.V. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4 (2005) 1281-1285
109. Rose K.M., Marin M., Kozak S.L., and Kabat D. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J. Biol. Chem. 279 (2004) 41744-41749
110. Rose K.M., Marin M., Kozak S.L., and Kabat D. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res. Hum. Retroviruses 21 (2005) 611-619
111. Sakuma R., Noser J.A., Ohmine S., and Ikeda Y. Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G. Gene Ther. 14 (2007) 185-189
112. Sarkis P.T., Ying S., Xu R., and Yu X.F. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 177 (2006) 4530-4540
113. Sasada A., Takaori-Kondo A., Shirakawa K., Kobayashi M., Abudu A., Hishizawa M., Imada K., Tanaka Y., and Uchiyama T. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2 (2005) 32
114. Sassaman D.M., Dombroski B.A., Moran J.V., Kimberland M.L., Naas T.P., DeBerardinis R.J., Gabriel A., Swergold G.D., and Kazazian Jr. H.H. Many human L1 elements are capable of retrotransposition. Nat. Genet. 16 (1997) 37-43
115. Sawyer S.L., Emerman M., and Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2 (2004) E275
116. Sayah D.M., Sokolskaja E., Berthoux L., and Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430 (2004) 569-573
117. Schrofelbauer B., Chen D., and Landau N.R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3927-3932
118. Schrofelbauer B., Yu Q., Zeitlin S.G., and Landau N.R. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79 (2005) 10978-10987
119. Schumacher A.J., Nissley D.V., and Harris R.S. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9854-9859
120. Schumann G.G. APOBEC3 proteins: major players in intracellular defence against LINE-1-mediated retrotransposition. Biochem. Soc. Trans. 35 (2007) 637-642
121. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
122. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., and Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278 (2003) 44412-44416
123. Shirakawa K., Takaori-Kondo A., Kobayashi M., Tomonaga M., Izumi T., Fukunaga K., Sasada A., Abudu A., Miyauchi Y., Akari H., Iwai K., and Uchiyama T. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 344 (2006) 263-266
124. Simon J.H., Gaddis N.C., Fouchier R.A., and Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4 (1998) 1397-1400
125. Smith H.C., Bottaro A., Sowden M.P., and Wedekind J.E. Activation induced deaminase: the importance of being specific. Trends Genet. 20 (2004) 224-227
126. Soros V.B., Yonemoto W., and Greene W.C. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3 (2007) e15
127. Stenglein M.D., and Harris R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281 (2006) 16837-16841
128. Stevenson M., Stanwick T.L., Dempsey M.P., and Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9 (1990) 1551-1560
129. Stopak K., de Noronha C., Yonemoto W., and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003) 591-601
130. Stopak K.S., Chiu Y.L., Kropp J., Grant R.M., and Greene W.C. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282 (2007) 3539-3546
131. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 427 (2004) 848-853
132. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., and Pathak V.K. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279 (2004) 35822-35828
133. Teixeira D., Sheth U., Valencia-Sanchez M.A., Brengues M., and Parker R. Processing bodies require RNA for assembly and contain nontranslating mRNAs. RNA 11 (2005) 371-382
134. Teng B., Burant C.F., and Davidson N.O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260 (1993) 1816-1819
135. Thielen B.K., Klein K.C., Walker L.W., Rieck M., Buckner J.H., Tomblingson G.W., and Lingappa J.R. T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog. 3 (2007) 1320-1334
136. Vartanian J.P., Meyerhans A., Asjo B., and Wain-Hobson S. Selection, recombination, and G → A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65 (1991) 1779-1788
137. Vartanian J.P., Henry M., and Wain-Hobson S. Sustained G → A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J. Gen. Virol. 83 (2002) 801-805
138. Wedekind J.E., Dance G.S., Sowden M.P., and Smith H.C. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19 (2003) 207-216
139. Wedekind J.E., Gillilan R., Janda A., Krucinska J., Salter J.D., Bennett R.P., Raina J., and Smith H.C. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 281 (2006) 38122-38126
140. Wichroski M.J., Ichiyama K., and Rana T.M. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280 (2005) 8387-8396
141. Wichroski M.J., Robb G.B., and Rana T.M. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2 (2006) e41
142. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
143. Wurtzer S., Goubard A., Mammano F., Saragosti S., Lecossier D., Hance A.J., and Clavel F. Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J. Virol. 80 (2006) 3679-3683
144. Xiao Z., Ehrlich E., Yu Y., Luo K., Wang T., Tian C., and Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349 (2006) 290-299
145. Xiao Z., Ehrlich E., Luo K., Xiong Y., and Yu X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21 (2007) 217-222
146. Xu H., Svarovskaia E.S., Barr R., Zhang Y., Khan M.A., Strebel K., and Pathak V.K. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5652-5657
147. Xu R., Zhang X., Zhang W., Fang Y., Zheng S., and Yu X.F. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B × antigen mutants and hepatocellular carcinoma. Hepatology 46 (2007) 1810-1820
148. Yang B., Chen K., Zhang C., Huang S., and Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282 (2007) 11667-11675
149. Ying S., Zhang X., Sarkis P.T., Xu R., and Yu X. Cell-specific regulation of APOBEC3F by interferons. Acta Biochim. Biophys. Sin. (Shanghai) 39 (2007) 297-304
150. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
151. Yu Q., Chen D., Konig R., Mariani R., Unutmaz D., and Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 (2004) 53379-53386
152. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., and Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 (2004) 435-442
153. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., and Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 (1990) 213-222
154. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
155. Zhang W., Zhang X., Tian C., Wang T., Sarkis P.T., Fang Y., Zheng S., Yu X.F., and Xu R. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol. 10 (2007) 112-121
156. Zheng Y.H., and Peterlin B.M. Intracellular immunity to HIV-1: newly defined retroviral battles inside infected cells. Retrovirology 2 (2005) 25
157. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., and Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 6073-6076
158. Zheng Y.H., Lovsin N., and Peterlin B.M. Newly identified host factors modulate HIV replication. Immunol. Lett. 97 (2005) 225-234